pharmaphorum Podcast

Earlier this year, the FDA released draft guidance endorsing Bayesian methods and simulation-based evidence in clinical trials in a significant shift in how regulators think about predictive medicine. 

In a new pharmaphorum podcast, Dr Irina Babina, CEO of oncology R&D platform Concr, discusses how current regulatory frameworks were built for static, one-test-one-answer diagnostics, as well as the potential of di...

*This episode of the pharmaphorum podcast is brought to you in association with Klick Health*

Europe continues to offer major life sciences advantages: deep scientific talent, strong clinical expertise, mature research infrastructure, and significant manufacturing capability. Indeed, biotech companies continue to invest in Europe as a long-term hub for scientific innovation, clinical research, and economic growth.

In a new pharmaph...

*This episode of the pharmaphorum podcast is brought to you in association with Klick Health*

When it comes to digital innovation and AI, consideration of using and implementing such responsibly and ethically ever more becomes forefront. But how can pharma lead the way in ethical AI and trust-driven innovation?

In a new pharmaphorum podcast, Erik Janssen, head of digital care transformation at UCB, joins web editor Nicole Raleigh ...

Public demand for prevention is surging, with 33.6 million people now using the NHS App, yet, NHS leaders say the digital infrastructure required to deliver prevention at scale isn’t in place.

In a new episode of the podcast, pharmaphorum spoke with James Davis, a healthcare expert at PA Consulting, for a conversation on the digital foundations needed to unlock a prevention first NHS.

Davis also discusses the initiatives with...

For a variety of reasons, early stage clinical trials have been moving out of the United States more and more over the past few years, as companies pursue savings and lighter regulatory burden in places like China and Australia. The industry has long urged the US government to take some action to make it more attractive to bring these trials back to the States. That's the broad idea behind Operation TRIALBLAZER, a campaign launched...

Chronic liver disease affects around 1.5 billion people globally. As understanding of liver disease improves, outcomes are increasingly determined by how early patients are identified, not just what therapies are available.

In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Lee Lehman Becker, Roche’s global head of healthcare insights at Roche Information Solutions (RIS), for a discussion of the liver diseas...

The drug price negotiation provisions in the Inflation Reduction Act were designed to continue evolving with each passing year. As CMS prepares for 2028 and 2029, the agency has put out new draft guidance codifying and, in some cases, modifying the fine print of the controversial law. They’ve also recently issued additional draft guidance on how they’ll handle the imminent introduction of Part B drugs into the programme...

SYNGAP1-related disorder negatively impacts synaptic signalling during critical periods of brain development, leading to a range of cognitive, epileptic, behavioural, and motor symptoms.

In a new episode of the pharmaphorum podcast, web editor Nicole Raleigh spoke with Kelly Gold, CFO of CAMP4 Therapeutics, about antisense oligonucleotides (or ASOs) - medicines designed to selectively restore natural protein production in diseases ...

The M&A market has been rebounding in the US, driven by factors like patent cliffs and improved balance sheets – but the question is whether this will play out in Europe and how the wave could differ.

In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Andrea Carta Mantiglia, partner and lead of the Healthcare & Life Sciences Focus Team at Italian law firm BonelliErede, about whether the current US bi...

Purespring Therapeutics is a precision nephrology company pioneering first-in-class, targeted genetic therapies designed to preserve kidney function.

In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Haseeb Ahmad, CEO of Purespring, who discusses transforming the treatment of kidney disease, an area of enormous unmet need, with more than 840 million people worldwide living with chronic kidney disease.

Indeed, Pur...

Europe's biotech sector is facing an innovation cliff, with fewer clinical starts, tighter capital, and increasing development complexity.

In a new pharmaphorum podcast, web editor Nicole Raleigh caught up with Paul Bridges, president, consulting, at Parexel, and Charlotte Moser, Parexel’s chief medical officer, following BIO-Europe Spring in Lisbon, Portugal.

The conversation touches upon regulatory strategy and evolving pol...

Cutaneous T-cell lymphoma (or CTCL) is a rare form of non-Hodgkin lymphoma that begins in T lymphocytes, a kind of white blood cell that plays a crucial role in the immune system. And Citius Oncology is focused on developing and commercialising a targeted immune therapy for the initial indication of the treatment of persistent or recurrent CTCL.

In a new pharmaphorum podcast, web editor Nicole Raleigh spoke with Leonard Mazur, CEO ...

The radiopharmaceutical sector is in the midst of a transformative year in 2026, with significant developments and challenges, including policy and reimbursement, increasing demand and growth within precision oncology and molecular imaging, and the need for specialised CDMOs when it comes to the intricate nature of radiopharmaceutical manufacturing.

In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Dr Andrew Cave...

2026 is the year of a major wave of pharmaceutical patent expirations, with numerous blockbuster drugs – spanning diabetes, immunology, cardiovascular, oncology, and other therapeutic areas – on the verge of losing market exclusivity.

In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Rebecca Guntern, chief commercial officer at Sandoz, for a conversation on the ‘golden decade’ for generics...

In a new pharmaphorum podcast, web editor Nicole Raleigh spoke with Lee-Ann Farrell, Head of National Programmes at Johnson & Johnson, about what delivery will look like in practice when it comes to the National Cancer Plan, the 10-Year Health Plan, and the Life Sciences Sector Plan.

The conversation ranges what comes next following the clear policy direction of the Plans, including how the system can move from ambition to impl...

In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Kris Kaneta, chief product officer at Norstella, which is helping life sciences companies speed up development with instant strategy recommendations.

Kaneta discusses AI in drug trials and commercialisation and just what’s possible when clinical AI has access to a data set robust enough to allow it to make real strategic recommendations.

Kaneta also tou...

In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Dr Ramy Younes, Corporate Vice President, Global Head of Clinical Development, CardioRenalMetabolism, at Boehringer Ingelheim.

The conversation explores the crisis beyond obesity that many clinicians and health systems are now grappling with: that obesity can’t be treated as a short-term, weight-loss lifestyle issue. Rather, it needs to be managed as a compl...

In a new pharmaphorum podcast, web editor Nicole Raleigh sat down with Dr Cedrik Britten, chief medical officer at Immatics, to discuss novel PRAME-directed T-cell immunotherapies.

Targeting PRAME unlocks new treatment options for a broad patient population with significant unmet medical need. And to do so safely and effectively requires deep expertise in immunology, drug development, and beyond.

Britten explains how finding the ri...

Longevity and healthspan have emerged rapidly as an increasingly serious category of healthcare study and investment. But there are a lot of ideas inside the industry and out about exactly what the goal is. Is it about extending lifespans as much as possible? Are we trying to live forever? Or do we just want to experience less physical and cognitive decline as we age?

In today’s episode of the pharmaphorum podcast, host Jonah...